Antibody-drug conjugate · developed by Dyne Therapeutics
Zeleciment Rostudirsen is an antibody drug conjugate studied in Duchenne muscular dystrophy, given by intravenous infusion.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07608432 | Phase 3 | Duchenne Muscular Dystrophy (DMD) | Recruiting | DYN |
| NCT05524883 | Phase 1/2 | Duchenne Muscular Dystrophy (DMD) | Active not recruiting | DYN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
DMDDuchenne Muscular Dystrophy (DMD)Genetic Disease, InbornGenetic Disease, X-LinkedMuscular DystrophiesMuscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)Muscular Dystrophy (DMD)Muscular Dystrophy in ChildrenMuscular Dystrophy, DuchenneMuscular Dystrophy, Duchenne and Becker TypesMuscular Dystrophy, Duchenne TypeNeuromuscular Diseases (NMD)
Updated Oct 11, 2026. Something wrong or missing? Report it on the DYN page.
See DYN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
DYN catalysts and pipeline →